Zai Lab (NASDAQ:ZLAB - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.19), Zacks reports. The firm had revenue of $109.07 million during the quarter, compared to analysts' expectations of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Zai Lab updated its FY 2025 guidance to EPS.
Zai Lab Trading Down 8.4 %
Shares of NASDAQ:ZLAB traded down $2.91 during midday trading on Monday, hitting $31.73. The stock had a trading volume of 1,536,211 shares, compared to its average volume of 889,028. The company has a market capitalization of $3.47 billion, a PE ratio of -11.45 and a beta of 1.02. Zai Lab has a 1 year low of $13.48 and a 1 year high of $36.60. The stock has a 50 day moving average price of $27.67 and a two-hundred day moving average price of $25.96.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on ZLAB. Cantor Fitzgerald raised shares of Zai Lab to a "strong-buy" rating in a report on Wednesday, February 5th. Bank of America restated a "neutral" rating and issued a $36.10 price objective (up from $29.00) on shares of Zai Lab in a research note on Monday.
Read Our Latest Stock Analysis on ZLAB
Insider Buying and Selling
In related news, insider Rafael Amado sold 7,583 shares of the company's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total transaction of $199,281.24. Following the transaction, the insider now owns 33,834 shares of the company's stock, valued at $889,157.52. This represents a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 13.88% of the stock is currently owned by corporate insiders.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Recommended Stories
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
